By June 19, 2019 Closed

Novartis Pharmaceuticals trial entitled: A randomized, double-blind, placebo- controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNFα agents

Join the discussion 8 Comments

Leave a Reply